Global burden of hypertension: analysis of world wide data. Lancet 2005 Jan 1521;365(9455):217-223.
Resistant hypertension: diagnosis, evaluation, and treatment—a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008 Jun 24;117(25):e510-526.
Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005 Nov;18(11):1422-1428.
Treatment resistant hypertensioninves tigation and conservative management. Dtsch Arztebl Int 2014 Jun 20;111(25):425-431.
Current status of lumbar sympathectomy. Am Surg 1976 Feb;42(2):89-91.
Sympathectomy for essential hypertension. Circulation 1952 Jul;6(1):131-140.
The effect on the kidney of bilateral splanchnicectomy in patients with hypertension. J Clin Invest 1937 Jan;16(1):49-65.
The influence of supradiaphragmatic splanchnicectomy on the heart in hypertension. Am Heart J 1948 Apr;35(4):567-583.
A surgical treatment of essential hypertension. J Clin Invest 1935 Jan;14(1):22-26.
Surgical treatment of hypertension. Am J Med 1948;4(5):744-759.
Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 2004 Feb;43(2):306-311.
Novel baroreflex activation therapy in resistant hypertension: results of a European multicenter feasibility study. J Am Coll Cardiol 2010 Oct 5;56(15):1254-1258.
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the doubleblind, randomized, placebocontrolled rheos pivotal trial. J Am Coll Cardiol 2011 Aug 9;58(7):765-773.
Baro-reflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos pivotal trial. J Am Soc Hypertens 2012 Mar-Apr;6(2):152-158.
Baro-reflex activation therapy safely reduces blood pressure for at least five years in a large resistant hypertension cohort. J Am Soc Hypertens 2014;8(4):e9-10.
Minimally inva sive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012 Jul-Aug;6(4):270-276.
Available at: https://clinicaltrials.gov/ct2/show/NCT01831895.
